- Conditions
- Inflammatory Bowel Diseases
- Interventions
- Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
- Biological
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
- Interventions
- Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2050
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Rheumatoid Arthritis
- Interventions
- Golimumab 100 mg, Golimumab 50 mg, Methotrexate, Placebo injection, Placebo capsules
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 13
- States / cities
- Mobile, Alabama • Palo Alto, California • Pasadena, California + 10 more
- Conditions
- Type 1 Diabetes (T1D)
- Interventions
- Golimumab, Placebo (matching golimumab)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 2 Years to 44 Years
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab, Golimumab, JNJ-78934804, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 703 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more
- Conditions
- Pre-Symptomatic Type 1 Diabetes
- Interventions
- Golimumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania • Charlottesville, Virginia
- Conditions
- Rheumatoid Arthritis
- Interventions
- Methotrexate, Abatacept, Adalimumab, Azathioprine, Baricitinib, Certolizumab, Etanercept, Golimumab, Hydroxychloroquine, Infliximab, Leflunomide, Minocycline, Rituximab, Sarilumab, Sulfasalazine, Tofacitinib
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Golimumab, Placebo
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 33
- States / cities
- Little Rock, Arkansas • Newport Beach, California • Sacramento, California + 30 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Placebo, Golimumab 50 mg, Golimumab 100 mg
- Drug · Biological
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 37 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo injections, Placebo capsules, Methotrexate capsules, Golimumab 50 mg injections, Golimumab 100 mg injections
- Drug · Biological
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Upland, California + 15 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Golimumab, Infliximab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 12
- States / cities
- San Francisco, California • Aurora, Colorado • Lone Tree, Colorado + 9 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Golimumab, Placebo, methotrexate (MTX)
- Drug · Other
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 592 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 9
- States / cities
- Daytona Beach, Florida • Miami, Florida • Palm Harbor, Florida + 6 more
- Conditions
- Juvenile Spondyloarthritis
- Interventions
- Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
- Conditions
- Rheumatic Disease
- Interventions
- Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
- Drug · Biological
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colitis, Ulcerative
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1, Golimumab Dose 2, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- San Diego, California • Colorado Springs, Colorado • Tampa, Florida + 11 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Guselkumab, Golimumab, JNJ-78934804, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 63
- States / cities
- Arcadia, California • Coronado, California • Lancaster, California + 54 more